What Is Semaglutide? Uses, Risks, and FDA Status
What Is Semaglutide?
Semaglutide is a GLP-1 receptor agonist — a synthetic peptide that mimics the incretin hormone glucagon-like peptide-1. Originally developed by Novo Nordisk, it is FDA-approved under the brand names Ozempic (for type 2 diabetes) and Wegovy (for chronic weight management). It has become one of the most prescribed peptide-based medications in the world, with significant public attention for its weight loss effects.
How Does Semaglutide Work?
Semaglutide works by binding to GLP-1 receptors in the pancreas, brain, and gut. In the pancreas, it stimulates insulin secretion and suppresses glucagon release, which lowers blood sugar. In the brain, it acts on appetite centers in the hypothalamus to reduce hunger and increase feelings of fullness. It also slows gastric emptying, meaning food stays in the stomach longer. The combined effect is reduced caloric intake and improved blood sugar control. Its long half-life (approximately 7 days) allows for once-weekly dosing.
What Is Semaglutide Used For?
Semaglutide has FDA-approved and investigational uses:
- Type 2 diabetes management — FDA-approved (Ozempic) for blood sugar control in adults with type 2 diabetes
- Chronic weight management — FDA-approved (Wegovy) for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition
- Cardiovascular risk reduction — The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events in overweight/obese adults (Lincoff et al., N Engl J Med, 2023)
- NASH/MASH — Under investigation for non-alcoholic steatohepatitis
- Alzheimer's disease — Early-stage clinical trials exploring neuroprotective effects
What Are the Risks?
- Gastrointestinal side effects. Nausea, vomiting, diarrhea, and constipation are the most common adverse effects, particularly during dose escalation.
- Pancreatitis risk. Cases of acute pancreatitis have been reported. Patients with a history of pancreatitis should use caution.
- Thyroid concerns. Animal studies showed an increased risk of thyroid C-cell tumors. Semaglutide carries a boxed warning and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2.
- Gallbladder events. Increased incidence of cholelithiasis (gallstones) has been observed in clinical trials.
- Muscle loss. Rapid weight loss may include loss of lean muscle mass. Resistance training and adequate protein intake are commonly recommended alongside treatment.
- Rebound weight gain. Studies suggest weight regain is common after discontinuation (Wilding et al., Diabetes Obes Metab, 2022).
FDA Status
Semaglutide is FDA-approved as a branded pharmaceutical (Ozempic, Wegovy, Rybelsus). Compounded versions have been available through 503A and 503B pharmacies during periods of branded drug shortage. The FDA has taken enforcement action against some compounders as shortage designations have changed. The regulatory status of compounded semaglutide is actively evolving — check current FDA shortage listings for the latest.
Key Takeaway
Semaglutide is an FDA-approved GLP-1 receptor agonist with strong clinical evidence for diabetes management and weight loss, though it carries meaningful side effects and its compounded availability depends on current shortage status.
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.